Dravet Syndrome Treatment Costs Drop Sharply... Expanded Health Insurance Coverage for Severe and Rare Disease Medications
Ministry of Health and Welfare Registers 'Fintepla Solution' in Just 126 Days
New Coverage for 'Polivy', Expanded Application for 'Blincyto'
Support for Stable Supply of Withdrawal-Prevention Medicines Also Strengthened
With the expansion of health insurance coverage for treatments targeting serious and rare diseases, the financial burden of high treatment costs on patients is set to decrease. In particular, a Dravet syndrome therapy was registered as a reimbursable drug through a pilot project that conducted approval, reimbursement review, and price negotiation simultaneously, allowing it to be listed for health insurance at nearly twice the speed compared to the previous process.
Starting September 1, the Ministry of Health and Welfare announced it will expand pharmaceutical reimbursement under the health insurance program to alleviate the treatment cost burden on patients with rare and intractable diseases and those with serious cancers. The Ministry also stated it would support the stable supply of essential medicines where supply disruptions are of concern.
With this expansion, health insurance will now cover Fintepla Oral Solution, a treatment for Dravet syndrome, a rare and intractable form of epilepsy. Dravet syndrome is a disease that manifests within a child's first year and leads to severe seizures and developmental delays. The estimated number of patients in Korea is about 150. Due to frequent, severe seizures, treatment is complex and the costs are considerable. Thanks to insurance coverage for Fintepla Oral Solution, the annual medical expense per patient, which was around 100 million won, is expected to be reduced to about 10 million won.
Notably, Fintepla Oral Solution was selected for the 'Simultaneous Approval-Evaluation-Negotiation Pilot Project' aimed at accelerating insurance reimbursement of drugs for critical illnesses. The product was approved by the Ministry of Food and Drug Safety, with the reimbursement review by the Health Insurance Review & Assessment Service and price negotiations with the National Health Insurance Service conducted simultaneously. As a result, insurance listing was completed in 126 days—significantly faster than the usual 240-day process.
For initial treatment of diffuse large B-cell lymphoma (DLBCL), a malignant blood cancer marked by abnormal B-cell proliferation, the newly developed drug Polivy Injection is now reimbursable. While initial treatment options have until now been limited, this reimbursement expansion is expected to provide patients with new therapeutic choices.
The scope of health insurance coverage for Blincyto Injection, a pediatric leukemia medication, will also be broadened. Previously, reimbursement for patients with precursor B-cell acute lymphoblastic leukemia was only available if the disease relapsed or did not respond to established treatments. Now, patients will be eligible for reimbursement even in the early stage to remove minimal residual disease following first-line chemotherapy, immediately after cancer cells have been eradicated. As this disease shows a higher incidence in children under five, the Ministry of Health and Welfare expects this move will help reduce the risk of early relapse and raise the chances of complete cure.
Efforts to support the stable supply of essential medicines will also be reinforced. The Ministry has newly designated JW Protamine 6% Injection—a drug vital for blood pressure regulation and circulatory stability in newborns and premature infants—as an 'exit prevention medication' where low profitability raises risks of discontinued production or import, and is implementing a cost compensation scheme. Tuberculin PPD AJV, an essential tuberculosis diagnostic reagent for which supply disruptions were expected due to increased import prices, will have those higher unit costs quickly reflected in this year's pricing to preempt any supply instability.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jooheon Yoo, Director-General for National Health Insurance Policy at the Ministry of Health and Welfare, stated, "Going forward, we will continue to promote rapid health insurance reimbursement for treatments of serious and rare diseases, while actively supporting stable supplies of other essential medicines needed for medical care."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.